ArticleClinical, cosmetic and investigational dermatology2026
Clinicopathological Features and Prognosis of Pediatric Mastocytosis: A 15-Year Experience with Emphasis on Disease Evolution.
Article in Clinical, cosmetic and investigational dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Mastocytosis is characterized by abnormal accumulation of mast cells in one or multiple organs. Pediatric-onset mastocytosis varies from adult type in the clinical manifestations and disease courses. Objective: To better understand the pediatric variants from adult mastocytosis, we performed a thorough study of mastocytosis subtypes. Methods: We retrospectively reviewed patients with mastocytosis beginning at ≤17 years of age who were evaluated in the Department of Dermatology between 2009 and 2025. Diagnoses and subtype classifications were established according to the 2022 World Health Organization (WHO) diagnostic criteria. Clinicopathological features, immunophenotypes, clinical outcomes, and potential prognostic factors were analyzed. Results: Fifty-two patients were included, with a male to female ratio of 2.25:1. Maculopapular cutaneous mastocytosis (MPCM) was the most common subtype, followed by cutaneous mastocytoma, diffuse cutaneous mastocytosis (DCM) and systemic mastocytosis. Among MPCM patients, 60.47% were classified as p-MPCM and 39.53% as m-MPCM. Compared to m-MPCM, p-MPCM showed more frequent extremity involvement (P=0.0037) and laboratory abnormalities. CD2 was expressed in 74.42% of pediatric mastocytosis, while CD25 and CD30 were expressed in a few congenital lesions with high mast cell burden. Four patients (11.76%) achieved complete remission, and 11 patients (32.35%) showed partial remission, whereas 19 patients (55.88%) had persistent lesions with non-remission or worsening condition. Kaplan-Meier analysis revealed no significant association between clinicopathological variables with clinical outcome. Conclusion: Chinese pediatric patients with mastocytosis in our cohort tend to have isolated CM without systemic involvement, significant predilection for male, and persistent clinical course with limited favorable outcomes. Pediatric mastocytosis exhibited distinct clinical manifestations and immunophenotypes in contrast to adult mastocytosis and Caucasian cohorts, suggesting age-related and population-related differences in disease evolution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.